Details Basic Details Approval Date Tuesday, October 17, 2023 Original Posting Date Friday, December 29, 2023 Health Outcome(s) serious infections, tuberculosis (TB), opportunistic infections, malignancy, hepatitis B reactivation, adverse pregnancy and fetal outcomes, hypersensitivity reactions, inflammatory bowel disease (IBD), drug induced liver injury, major adverse cardiovascular events, hematologic adverse reactions Regulatory Link(s) (2) FDA Approval Package ARIA Memo